Your browser doesn't support javascript.
loading
Lower complement C1q levels in first-episode psychosis and in schizophrenia.
Koskuvi, Marja; Malwade, Susmita; Gracias Lekander, Jessica; Hörbeck, Elin; Bruno, Sanna; Holmen Larsson, Jessica; Pelanis, Aurimantas; Isgren, Anniella; Goulding, Anneli; Fatouros-Bergman, Helena; Schalling, Martin; Piehl, Fredrik; Erhardt, Sophie; Landen, Mikael; Cervenka, Simon; Orhan, Funda; Sellgren, Carl M.
Afiliação
  • Koskuvi M; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Malwade S; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Gracias Lekander J; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Hörbeck E; The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Department of Psychotic Disorders, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Bruno S; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Holmen Larsson J; The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
  • Pelanis A; Department of Anesthesiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Isgren A; The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Department of Psychotic Disorders, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Goulding A; Department of Psychotic Disorders, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychology, University of Gothenburg, Gothenburg, Sweden.
  • Fatouros-Bergman H; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
  • Samudyata; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Schalling M; Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.
  • Piehl F; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Erhardt S; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Landen M; The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Cervenka S; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden; Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.
  • Orhan F; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Sellgren CM; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden. Electronic address: carl.sellgren@ki.se.
Brain Behav Immun ; 117: 313-319, 2024 03.
Article em En | MEDLINE | ID: mdl-38301948
ABSTRACT
Recent evidence has implicated complement component (C) 4A in excessive elimination of synapses in schizophrenia. C4A is believed to contribute to physiological synapse removal through signaling within the C1q initiated classical activation axis of the complement system. So far, a potential involvement of C1q in the pathophysiology of schizophrenia remains unclear. In this study, we first utilized large-scale gene expression datasets (n = 586 patients with schizophrenia and n = 986 controls) to observe lower C1QA mRNA expression in prefrontal cortex tissue of individuals with schizophrenia (P = 4.8x10-05), while C1QA seeded co-expression networks displayed no enrichment for schizophrenia risk variants beyond C4A. We then used targeted liquid chromatography-mass spectrometry (LS-MS) to measure cerebrospinal fluid (CSF) levels of C1qA in 113 individuals with first-episode psychosis (FEP), among which 66 individuals was later diagnosed with schizophrenia, and 87 healthy controls. CSF concentrations of C1qA were lower in individuals diagnosed with FEP (P = 0.0001), also after removing subjects with a short-term prescription of an antipsychotic agent (P = 0.0005). We conclude that C1q mRNA and protein levels are lower in schizophrenia and that further experimental studies are needed to understand the functional implications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Antipsicóticos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Antipsicóticos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article